An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells.
View/ Open
Date
2021-09-01ICR Author
Author
Zhang, J
Jain, A
Milhas, S
Williamson, DJ
Mysliwy, J
Lodge, A
Thirlway, J
Al Nakeeb, M
Miller, A
Rabbitts, TH
Type
Journal Article
Metadata
Show full item recordAbstract
Refractory T cell acute leukaemias that no longer respond to treatment would benefit from new modalities that target T cell-specific surface proteins. T cell associated surface proteins (the surfaceome) offer possible therapy targets to reduce tumour burden but also target the leukaemia-initiating cells from which tumours recur. Recent studies of the T cell leukaemia surfaceome confirmed that CD7 is highly expressed in overt disease. We have used an anti-CD7 antibody drug conjugate (ADC) to show that the binding of antibody to surface CD7 protein results in rapid internalization of the antigen together with the ADC. As a consequence, cell killing was observed via induction of apoptosis and was dependent on cell surface CD7. The in vitro cytotoxic activity (EC50) of the anti-CD7 ADC on T cell acute leukaemia (T-ALL) cells Jurkat and KOPT-K1 was found to be in the range of 5-8 ng/mL. In a pre-clinical xenograft model of human tumour growth expressing CD7 antigen, growth was curtailed by a single dose of ADC. The data indicate that CD7 targeting ADCs may be developed into an important second stage therapy for T cell acute leukaemia, for refractory CD7-positive leukaemias and for subsets of acute myeloid leukaemia (AML) expressing CD7.
Collections
Research team
Chromosomal Translocations and Intracellular Antibody Therapeutics
Chromosomal Translocations and Intracellular Antibody Therapeutics
Language
eng
Date accepted
2021-05-14
License start date
2021-05-18
Citation
Leukemia research, 2021, 108 pp. 106626 - ?
Publisher
PERGAMON-ELSEVIER SCIENCE LTD